OTCMKTS:IDRSF Idorsia (IDRSF) Stock Price, News & Analysis → Don’t buy Gold until you see this (From The TradingPub) (Ad) Free IDRSF Stock Alerts $2.25 -0.19 (-7.79%) (As of 05/31/2024 08:51 PM ET) Add Compare Share Share Today's Range$2.25▼$2.2550-Day Range$1.95▼$2.8052-Week Range$1.40▼$9.00Volume1,500 shsAverage Volume3,051 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Idorsia alerts: Email Address Ad Wealthpin ProDo This Before July 30 2024 To Claim Trump’s Gift In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Idorsia Stock (OTCMKTS:IDRSF)Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.Read More IDRSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDRSF Stock News HeadlinesJune 3 at 5:40 AM | americanbankingnews.comShort Interest in Idorsia Ltd (OTCMKTS:IDRSF) Grows By 9.6%May 24, 2024 | finance.yahoo.comIdorsia Ltd (IDRSF)May 23, 2024 | globenewswire.comIdorsia issues invitation to the 2024 Annual General Meeting of ShareholdersMay 21, 2024 | globenewswire.comIdorsia announces changes to Idorsia Executive Committee and Board of DirectorsMay 21, 2024 | globenewswire.comIdorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable valueMay 14, 2024 | globenewswire.comInvitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference callMay 1, 2024 | globenewswire.comIdorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bondApril 27, 2024 | finance.yahoo.comIdorsia Ltd (VTX:IDIA) Analysts Just Cut Their EPS Forecasts SubstantiallyApril 26, 2024 | finance.yahoo.comJERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertensionApril 23, 2024 | globenewswire.comIdorsia publishes an invitation to a bondholder meetingApril 17, 2024 | finance.yahoo.comIdorsia publishes a Financial Status required for an upcoming bondholder meetingApril 11, 2024 | globenewswire.comIdorsia takes steps to address short-term liquidity needsMarch 22, 2024 | bizjournals.comIdorsia gets FDA approval for high blood pressure drug TryvioMarch 22, 2024 | seekingalpha.comIdorsia: Aprocitentan Approval Is A Vital NewsMarch 22, 2024 | globenewswire.comIdorsia thanks Guy Braunstein for his years of service as he retiresMarch 20, 2024 | msn.comFDA approves Idorsia’s once-daily antihypertensive TryvioMarch 20, 2024 | msn.comIdorsia gets FDA approval for hypertension drug TryvioMarch 20, 2024 | finance.yahoo.comIdorsia Ltd (IDRSF) Stock Historical Prices & Data - Yahoo FinanceMarch 20, 2024 | globenewswire.comUS FDA approves Idorsia's once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensivesMarch 8, 2024 | finance.yahoo.comWhat Does The Future Hold For Idorsia Ltd (VTX:IDIA)? These Analysts Have Been Cutting Their EstimatesMarch 7, 2024 | realmoney.thestreet.comKepler Cheuvreux gets more bullish on Idorsia, upgrades sharesFebruary 28, 2024 | markets.businessinsider.comViatris, Idorsia Announce Global Research And Development CollaborationFebruary 6, 2024 | markets.businessinsider.comHere's what to expect from Idorsia's earningsJanuary 10, 2024 | finance.yahoo.comIdorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creationDecember 6, 2023 | finance.yahoo.comIdorsia Ltd (VTX:IDIA) surges 19%; individual investors who own 41% shares profited along with insidersSee More Headlines Receive IDRSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:IDRSF CUSIPN/A CIKN/A Webwww.idorsia.com Phone(158) 844-0000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Jean-Paul Clozel M.D. (Age 69)CEO & Executive Director Comp: $1.5MMr. André C. Muller (Age 61)Executive VP & CFO Dr. Martine Clozel (Age 69)Executive VP & Chief Scientific Officer Mr. Andrew C. Weiss (Age 56)Senior VP and Head of Investor Relations & Corporate Communications Mr. Julien Gander L.L.M. (Age 45)Senior VP, Group General Counsel & Company Secretary Mr. Alexander Khatuntsev (Age 46)Senior VP & Head of Global Human Resources Dr. Guy Braunstein M.D. (Age 68)Executive VP & Chief Medical Officer Mr. Olivier Lambert (Age 58)Senior VP & Head of Technical Operations Mr. Markus A. Riederer (Age 62)Senior VP & Head of Drug Discovery Biology Mr. Christoph Boss (Age 56)Senior VP & Head of Drug Discovery Chemistry More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors IDRSF Stock Analysis - Frequently Asked Questions Should I buy or sell Idorsia stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Idorsia in the last twelve months. There are currently 2 sell ratings for the stock. The consensus among Wall Street research analysts is that investors should "sell" IDRSF shares. View IDRSF analyst ratings or view top-rated stocks. How have IDRSF shares performed in 2024? Idorsia's stock was trading at $2.45 at the beginning of the year. Since then, IDRSF shares have decreased by 8.2% and is now trading at $2.25. View the best growth stocks for 2024 here. Are investors shorting Idorsia? Idorsia saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 7,663,900 shares, an increase of 9.6% from the April 30th total of 6,992,900 shares. Based on an average trading volume of 600 shares, the days-to-cover ratio is currently 12,773.2 days. View Idorsia's Short Interest. How do I buy shares of Idorsia? Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IDRSF) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyTrump conviction scandal exposedPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idorsia Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.